HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
HQY
HealthEquity, Inc.
HQY's fundamentals are strong and it looks cheap: trading at 37x earnings, less than half its usual 88x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
HQY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Healthy |
HQY's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
HQY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $103 | — |
| Current | 37x | $103 | — |
| Cheap | 41x | $112 | +9% |
| Fair | 87x | $242 | +135% |
| Expensive | 1,293x | $3,580 | +3374% |
Historical ranges are pointers, not guarantees.
HQY's PE is in its cheap range at 37x. If earnings grow as analysts expect, today's price would be 20x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
HQY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
HQY has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
HQY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.23 | +89% |
| Q3 2026 | $2.77 | +68% |
| Q2 2026 | $2.67 | +95% |
| Q1 2026 | $2.46 | +126% |
| Q4 2025 | $2.18 | +100% |
| Q3 2025 | $1.65 | +38% |
| Q2 2025 | $1.37 | +49% |
| Q1 2025 | $1.09 | +70% |
| Q4 2024 | $1.09 | +221% |
HQY has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over HQY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
HQY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.7M | +7.6% |
| Q2 2026 | $354.6M | +7.2% |
| Q1 2026 | $334.6M | +7.3% |
| Q4 2025 | $322.2M | +7.2% |
| Q3 2025 | $325.8M | +8.6% |
| Q2 2025 | $330.8M | +15% |
| Q1 2025 | $311.8M | +19% |
| Q4 2024 | $300.4M | +21% |
HQY's revenue has grown year over year for 21 quarters in a row: $351M last quarter, up 7.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 28% | +0.6 points |
| Q2 2026 | 29% | +3.9 points |
| Q1 2026 | 21% | +7.7 points |
| Q4 2025 | 24% | +18 points |
| Q3 2025 | 28% | +7.9 points |
| Q2 2025 | 25% | +11 points |
| Q1 2025 | 14% | -1.3 points |
| Q4 2024 | 6.5% | -5.9 points |
HQY has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over HQY on cash flow, with more consistent year-over-year improvement.
HQY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $135.2M | +0.1% |
| Q2 2026 | $97.2M | +50% |
| Q1 2026 | $117.6M | +56% |
| Q4 2025 | $137.8M | +53% |
| Q3 2025 | $135.1M | +26% |
| Q2 2025 | $64.7M | -0.1% |
| Q1 2025 | $75.4M | -1.4% |
| Q4 2024 | $90.3M | +60% |
HQY's free cash flow has been positive every quarter for seven years: $488M over the past year, up 33% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over HQY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
HQY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -992K shares |
| 1 year | -4.3% | -3.7M shares |
| 3 years | -2.7% | -2.3M shares |
| 5 years | +0.6% | +533K shares |
| Available history | +19% | +13.5M shares |
HQY has 84M diluted shares, down 4.3% from a year ago, with $404M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $107.7M |
| Q2 2026 | $123.3M |
| Q1 2026 | $81M |
| Q4 2025 | $92.4M |
| Q3 2025 | $66.7M |
| Q2 2025 | $59.1M |
| Q1 2025 | $63M |
HQY spent $404M buying back its own shares over the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
HQY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.3x | Healthy |
| Q2 2026 | 1.4x | Healthy |
| Q1 2026 | 1.3x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.8x | Healthy |
| Q2 2025 | 2.1x | Moderate |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.4x | Moderate |
HQY's net debt is about 1.3 years of its operating earnings (EBITDA), down from 1.8 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
HQY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.9 | Neutral |
| Stochastic | 73.0 | Neutral |
HQY's weekly RSI is 60 (neutral) and its Stochastic is 73 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
HQY PE vs Healthcare Sector
| Metric | HQY | Sector median | Relative |
|---|---|---|---|
| PE | 37x | 26x | 44% above |
| PE % | 13 | 29 | 16 pts below |
HQY is trading at 37x earnings, a 44% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
HQY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $97.0 | 6.2% above |
| 20 week MA | $97.9 | 5.3% above |
| 50 week MA | $90.3 | 14% above |
| 100 week MA | $93.5 | 10% above |
| 200 week MA | $83.2 | 24% above |
HQY has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
HQY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $74.0 | $68.3 | -7.7% |
| 2021 | $68.3 | $44.9 | -34% |
| 2022 | $44.9 | $61.6 | +37% |
| 2023 | $61.6 | $66.3 | +7.6% |
| 2024 | $66.3 | $96.3 | +45% |
| 2025 | $96.3 | $93.5 | -2.9% |
| 2026 YTD | $93.5 | $103.1 | +10% |
HQY has the edge over HIMS on returns for 2026, with the stronger performance.